Semaglutide at Cornerstone HealthMD

One Family of Medicines, Many Paths to Feeling Better

If you’ve been trying to lose weight or manage type 2 diabetes and feel like your body is fighting you, you’re not imagining it.
Hunger hormones, blood sugar swings, stress, sleep, genetics—so many things pull you in the opposite direction of where you want to go.

The good news: we finally have medicines that work with those hormones instead of against you.
One of the most important groups is semaglutide, the active ingredient in:

  • Wegovy® – approved for chronic weight management
  • Ozempic® – approved for type 2 diabetes (and often leads to weight loss)
  • Rybelsus® – an oral (tablet) form for type 2 diabetes

At Cornerstone HealthMD, we use semaglutide thoughtfully, never as a quick-fix shot, but as part of a long-term, compassionate plan for your health.

How Semaglutide Works

Semaglutide is a medication that acts like a hormone your body already makes, called GLP-1. GLP-1 is released from your gut after you eat and sends signals to your brain and pancreas that say:

  • “You’re getting full, slow down.”
  • “Let’s release insulin in a smarter way.”
  • “Don’t let blood sugar spike too high.”

By mimicking GLP-1, semaglutide can:

  • Reduce hunger and cravings
  • Help you feel full with smaller portions
  • Slow stomach emptying, so food sticks with you longer
  • Improve blood sugar control by boosting insulin response and lowering glucagon

Different brand names simply package semaglutide in different ways:

  • Wegovy – once-weekly injection, higher dose, specifically for chronic weight management
  • Ozempic – once-weekly injection for type 2 diabetes, with meaningful weight loss as an added benefit
  • Rybelsus – once-daily tablet, for people who prefer an oral option for type 2 diabetes

Wegovy®: Semaglutide for Chronic Weight Management

What it’s approved for
Wegovy is FDA-approved to help adults (and certain adolescents) with obesity, or overweight plus weight-related medical problems—lose weight and keep it off when combined with healthy eating and increased activity.

What the STEP Trials Showed

In the STEP program of clinical trials, thousands of adults received Wegovy 2.4 mg once weekly plus lifestyle support for 68 weeks.

  • In STEP 1, adults with obesity or overweight lost an average of about 14.9% of their body weight on semaglutide vs 2.4% with placebo.
  • More than 86% of people on Wegovy lost at least 5% of their starting weight, around 69% lost 10% or more, and about 50% lost 15% or more far more than placebo.

Longer follow-up showed that weight loss stayed substantial over about 2 years as long as semaglutide was continued. When medication was stopped, many people regained a significant portion of the lost weight, which tells us obesity is a chronic condition, not a short-term project.

To make this real:
If you start at 240 lb, a 15% weight loss is 36 lb, down to 204 lb, often enough to change how you move, sleep, and see yourself.

Heart Protection, Not Just Weight Loss

In 2024, Wegovy became the first weight-loss medication approved to reduce the risk of serious heart problems—heart attack, stroke, or cardiovascular death, in adults with obesity or overweight and established cardiovascular disease.

That means Wegovy isn’t just about the number on the scale; it’s also about protecting your heart.

Ozempic®: Semaglutide for Type 2 Diabetes (With Weight Benefits)

What it’s approved for
Ozempic is approved to:

  • Improve blood sugar in adults with type 2 diabetes
  • Reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and known heart disease.

Diabetes + Heart + Weight

In the SUSTAIN program and the SUSTAIN-6 cardiovascular outcomes trial:

  • Ozempic significantly lowered HbA1c (often by around 1–1.5 percentage points or more) compared with placebo or other drugs.
  • People on Ozempic often lost 4–6 kg (9–13 lb), depending on dose and study, compared to little or no weight loss in control groups.
  • SUSTAIN-6 showed a significant reduction in major cardiovascular events (MACE) vs placebo in high-risk patients with type 2 diabetes.

For many people, Ozempic improves blood pressure, cholesterol, and waist circumference as blood sugar and weight come down together.

At Cornerstone, we may consider Ozempic when:

  • Type 2 diabetes is a primary concern
  • There is existing heart disease or high cardiovascular risk
  • Weight loss is desired, but diabetes and heart protection are front and center

Any use beyond its approved diabetes indications (for weight alone) is considered off-label and is only done after careful discussion of risks, benefits, and alternatives.

Rybelsus®: The Oral Semaglutide Option

For people who prefer not to use injections, Rybelsus offers semaglutide in a once-daily tablet for type 2 diabetes.

What the PIONEER Trials Found

Across multiple PIONEER trials:

  • Oral semaglutide 14 mg daily significantly lowered HbA1c more than placebo and many other oral diabetes medications.
  • People typically lost 2–4 kg (4–9 lb) of body weight, sometimes more, depending on the study and comparison drug.
  • In PIONEER-4, oral semaglutide was noninferior to injectable liraglutide for blood sugar control and led to slightly greater weight loss at 52 weeks.

Rybelsus must be taken on an empty stomach with a small amount of water and waiting time before food, so it requires a bit more daily routine—but it’s a good fit for people who strongly prefer pills over injections.

What All Semaglutide Options Have in Common

Across Wegovy, Ozempic, and Rybelsus, we see certain themes:

Benefits

  • Meaningful weight loss – especially with Wegovy, where many patients lose 10–15% or more of their starting weight.
  • Better blood sugar control – lower A1c, fewer spikes, improved insulin sensitivity.
  • Cardiometabolic improvements – better cholesterol, blood pressure, and waist circumference in many patients.
  • Potential heart protection – proven for Ozempic in diabetes and for Wegovy in obesity + established cardiovascular disease.

Limitations and Side Effects

  • Common side effects: nausea, vomiting, diarrhea, constipation, bloating, or stomach pain, usually more noticeable when starting or increasing dose.
  • Rare but serious risks: pancreatitis, gallbladder disease, possible worsening of diabetic retinopathy in some patients with very rapid A1c drops, and very rare allergic reactions.
  • Not for everyone: these medications are typically avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and they are not used in pregnancy.
  • Weight regain when stopped: because semaglutide treats the biology of obesity, not just appetite for a few weeks, stopping the medication often leads to partial or full weight regain over time.

This is why major organizations (including the WHO) now emphasize that GLP-1 therapies should be viewed as part of long-term, chronic disease management, not a short “detox” or quick fix.

Is Semaglutide Right for You?

Semaglutide is powerful, but it isn’t perfect and it isn’t for everyone.
But if you’ve felt stuck, defeated, or blamed for your weight or blood sugar, you deserve a chance to see what happens when science and support are on your side.